Literature DB >> 23661651

Symptomatic lobar intracerebral haemorrhage preceded by transient focal neurological episodes.

Robert Hurford1, Andreas Charidimou, David Werring.   

Abstract

We report the case of a symptomatic intracerebral haemorrhage (ICH) in an elderly woman, secondary to cerebral amyloid angiopathy (CAA), and present the relevant imaging. A few months before, our patient experienced multiple, stereotyped, brief episodes of spreading paraesthesias, which were considered to be transient ischaemic attacks (TIAs) and treated with antithrombotic agents. In this case report, we explore CAA, a highly prevalent but under-recognised form of small vessel cerebrovascular disease and common cause of ICH. We then briefly discuss the clinical significance of transient focal neurological episodes in the context of CAA, as potential warning signs of future ICH. An important clinical message is that misdiagnosis of CAA-related focal neurological symptoms as TIAs (and prescribing antithrombotic drugs) could lead to potentially avoidable ICH. We also provide the current evidence base for the acute and secondary prevention treatment of patients with lobar ICH attributed to CAA, and discuss the prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23661651      PMCID: PMC3669767          DOI: 10.1136/bcr-2013-008687

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  22 in total

1.  Superficial siderosis.

Authors:  N Kumar; A A Cohen-Gadol; R A Wright; G M Miller; D G Piepgras; J E Ahlskog
Journal:  Neurology       Date:  2006-04-25       Impact factor: 9.910

Review 2.  Subarachnoid haemorrhage.

Authors:  Jan van Gijn; Richard S Kerr; Gabriel J E Rinkel
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

3.  Postoperative outcome of 37 patients with lobar intracerebral hemorrhage related to cerebral amyloid angiopathy.

Authors:  A Izumihara; T Ishihara; N Iwamoto; K Yamashita; H Ito
Journal:  Stroke       Date:  1999-01       Impact factor: 7.914

Review 4.  Intracerebral haemorrhage.

Authors:  Adnan I Qureshi; A David Mendelow; Daniel F Hanley
Journal:  Lancet       Date:  2009-05-09       Impact factor: 79.321

5.  Management patterns and health care use after intracerebral hemorrhage. a cost-of-illness study from a societal perspective in Germany.

Authors:  Christian Weimar; Carsten Weber; Markus Wagner; Otto Busse; Roman Ludwig Haberl; Karl W Lauterbach; Hans Christoph Diener
Journal:  Cerebrovasc Dis       Date:  2003       Impact factor: 2.762

6.  Subarachnoid hemosiderosis and superficial cortical hemosiderosis in cerebral amyloid angiopathy.

Authors:  J Linn; J Herms; M Dichgans; H Brückmann; G Fesl; T Freilinger; M Wiesmann
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-18       Impact factor: 3.825

7.  The clinical spectrum of cerebral amyloid angiopathy: presentations without lobar hemorrhage.

Authors:  S M Greenberg; J P Vonsattel; J W Stakes; M Gruber; S P Finklestein
Journal:  Neurology       Date:  1993-10       Impact factor: 9.910

8.  Effects of perindopril-based lowering of blood pressure on intracerebral hemorrhage related to amyloid angiopathy: the PROGRESS trial.

Authors:  Hisatomi Arima; Christophe Tzourio; Craig Anderson; Mark Woodward; Marie-Germaine Bousser; Stephen MacMahon; Bruce Neal; John Chalmers
Journal:  Stroke       Date:  2009-12-31       Impact factor: 7.914

9.  Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial.

Authors:  Craig S Anderson; Yining Huang; Ji Guang Wang; Hisatomi Arima; Bruce Neal; Bin Peng; Emma Heeley; Christian Skulina; Mark W Parsons; Jong Sung Kim; Qing Ling Tao; Yue Chun Li; Jian Dong Jiang; Li Wen Tai; Jin Li Zhang; En Xu; Yan Cheng; Stephane Heritier; Lewis B Morgenstern; John Chalmers
Journal:  Lancet Neurol       Date:  2008-04-07       Impact factor: 44.182

Review 10.  Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses.

Authors:  R G Hart; B S Boop; D C Anderson
Journal:  Stroke       Date:  1995-08       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.